Clinical Trials Logo

Memory Impairment clinical trials

View clinical trials related to Memory Impairment.

Filter by:

NCT ID: NCT02433691 Completed - Memory Impairment Clinical Trials

Memory and Exercise Training Study in Older Adults With Subjective Memory Complaints

MET
Start date: January 2015
Phase: N/A
Study type: Interventional

This pilot study is a first step in a rapidly growing area of clinical research to create the most effective means to combat age-related losses in cognitive function through preventive lifestyle strategies such as physical exercise and memory training. This study will develop innovative simultaneous exercise and memory training programs in non-demented volunteers with subjective memory complaints (controls or MCI). Our primary goal is to assess the cognitive impact of 4-week memory training programs done twice weekly: 1. during simultaneous aerobic exercise (SIM-AR-MET), 2. sequentially after aerobic exercise (SEQ-AR-MET), or 3. without aerobic exercise (replaced with sequential stretching and toning) (SEQ-ST-MET). The investigators will also measure potential metabolic (e.g., glucose, lipid panel) and molecular (serum BDNF) mediators of observed cognitive changes in a subset of participants (those at the UCLA CTRC/IPCN site).

NCT ID: NCT02301247 Completed - Memory Impairment Clinical Trials

Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)

Start date: November 2014
Phase: N/A
Study type: Interventional

This study is a double-blind placebo-controlled randomized clinical trial (RCT) to provide Class I evidence in support of or in refute of the efficacy of the modified Story Memory Technique (mSMT) in persons with progressive MS, with outcome measured through three mechanisms: (1) a traditional neuropsychological evaluation (NPE) (2) an assessment of global functioning (AGF) examining the impact of the treatment on daily activities, and (3) an optional functional magnetic resonance imaging (fMRI) scan.

NCT ID: NCT02265757 Completed - Clinical trials for Mild Cognitive Impairment

Behavioral Interventions to Prevent or Delay Dementia

Start date: June 2014
Phase: N/A
Study type: Interventional

This study will compare the effectiveness of different combinations of 5 types of behavioral interventions across patient-centered outcomes. It will also evaluate which outcomes (e.g. quality of life, cognition, function, mood) matter most to people at risk for dementia and their care partners. The results of this study have the potential to direct patients, families, and health care providers as to which combinations of behavioral interventions provide the greatest potential impact on which dementia prevention outcomes. Greater use of behavioral strategies that are targeted to the outcomes of most important to the patient will likely improve patient compliance and treatment adherence. This, in turn, can lessen the need for medication, health care, and long term care utilization.

NCT ID: NCT02193269 Completed - Memory Impairment Clinical Trials

The Effects of Minocycline in Humans

Start date: July 8, 2013
Phase: Phase 1
Study type: Interventional

To determine minocycline's effects on cognitive performance and measures of mood in abstinent cocaine users. Minocycline is a tetracycline derivative antibiotic that also inhibits microglia activation and the release of pro-inflammatory cytokines, chemokines, and nitric oxide (NO) production. Previous animal and human studies suggest that minocycline may have utility as a treatment for cocaine addiction.

NCT ID: NCT02051335 Completed - Alzheimer's Disease Clinical Trials

Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

Start date: January 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil.

NCT ID: NCT01965756 Completed - Dementia Clinical Trials

Effect of Insulin Sensitizer Metformin on AD Biomarkers

Start date: January 2013
Phase: Phase 2
Study type: Interventional

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive loss of memory and other cognitive functions. It is the most common cause of dementia in older adults, affecting approximately 18 million people worldwide, including almost 500,000 in the Philadelphia tri-state area. After age 65, the incidence of AD rises exponentially, doubling every five years. By age 85, almost half of us will have AD. In 2030, as many as 7.7 million Americans could have AD, and by 2050 this number could rise to 11-16 million people. The annual cost of AD in the United States is about $200 billion. AD-related medical complications are among the most common causes of death in the elderly population. Despite these alarming statistics, a "cure" for AD may not be essential since delaying the onset of AD by just 5 years could have a profound impact on this disorder by reducing the incidence and cost of AD by 50% between now and 2050. AD is difficult to recognize in its earliest stages, in which the principal complaint is typically an increase in episodes of forgetfulness. This stage is now commonly referred to as mild cognitive impairment (MCI). Neuroimaging and CSF biomarkers have demonstrated good accuracy in predicting which MCI patients later "convert" to AD and which tend to remain stable or revert to more normal cognition. The diagnosis of AD itself is made when increased loss of memory and other cognitive abilities (eg, language, praxis, and executive function) affect daily functioning. As the symptoms of dementia inevitably worsen, patients may become incapable of even basic activities such as feeding and dressing themselves. The disease course often spans more than a decade, creating a vast social and financial burden on society and extracting an immeasurable emotional toll on family members. Clinical and preclinical evidence is accumulating that brain insulin resistance may play a role in the pathogenesis and/or progression of Alzheimer's disease and that ameliorating insulin action in the brain may benefit cognition symptomatically and modify disease pathology.

NCT ID: NCT01828515 Completed - Memory Impairment Clinical Trials

Vilazodone for Corticosteroid-Induced Memory Impairment

Start date: December 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine whether vilazodone attenuates the memory and mood effects of corticosteroids on the human hippocampus in 24 healthy controls.

NCT ID: NCT01708304 Completed - Dementia Clinical Trials

Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)

RDAD
Start date: November 2012
Phase: N/A
Study type: Interventional

The University of Washington's Northwest Research Group on Aging is partnering with Area Agencies on Aging (AAA) in Washington and Oregon to complete this translational investigation of RDAD (Reducing Disabilities in Alzheimer's Disease). RDAD is an evidence-based program with demonstrated efficacy in helping older adults with dementia maintain physical function and remain physically and mentally healthy. This study asks two questions: 1) Can AAA partners successfully translate and implement RDAD, and 2) Is AAA implementation of RDAD effective in producing desired outcomes among agencies, providers, and older adults with dementia and their family members. This study is being conducted in Washington and Oregon states.

NCT ID: NCT01492738 Completed - Anxiety Clinical Trials

The Effect of Acupuncture on Anxiety and Working Memory

Start date: February 2011
Phase: N/A
Study type: Interventional

This study endeavors to examine the relationship between acupuncture, anxiety, and performance on a test of working memory. In the study, all participants will complete the State-Trait Anxiety Inventory (STAI) survey to determine how anxious they are at the moment and how anxious they tend to be in general. Then ½ of subjects will receive acupuncture for 20 minutes and ½ will rest quietly for 20 minutes. After this period, all subjects will again complete the STAI survey. Then all subjects will complete the Automated Operations Span Task (AOSPAN) which is a computerized test of working memory. Statistical analysis will be performed to determine if acupuncture had any effect on State-level anxiety and on performance on the AOSPAN.

NCT ID: NCT01364753 Completed - Memory Impairment Clinical Trials

Age-related Longitudinal Changes in Aviator Performance

Start date: January 2006
Phase: N/A
Study type: Observational

Our overall goal has been twofold: 1) to evaluate whether there are significant age-related changes in flight simulator performance near age 60, and 2) to assess whether there is an alternative model that can explain longitudinal flight simulator performance on the basis of measures of cognitive function and expertise.